GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
Provider: View Press Release Type: Link Title: GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab | GSK Description: GlaxoSmithKline plc and Vir Biotechnology, Inc. announce the supply of 220,000 doses of sotrovimab for adults and adolescents with COVID-19.
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Provider: View Press Release Type: Link Title: Shingrix approved in the US for prevention of shingles in immunocompromised adults | GSK Description: Immunocompromised individuals are at greater risk of shingles and associated complications than immunocompetent individuals
Brian McNamara appointed CEO Designate of new independent Consumer Healthcare company
Provider: View Press Release Type: Link Title: Brian McNamara appointed CEO Designate of new independent Consumer Healthcare company | GSK Description: Brian McNamara, the CEO of GSK Consumer Healthcare, has been appointed as CEO Designate of the new Consumer Healthcare company.
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
Provider: View Press Release Type: Link Title: ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs | GSK Description: ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
Provider: View Press Release Type: Link Title: ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19 | GSK Description: ViiV Healthcare today presented positive findings from the CUSTOMIZE trial
